Option Care Health
Option Care Health's revenue rose 13.0% to $5.6 billion in fiscal 2025. Its operating margin was 6.0%, down from 6.4% a year earlier. Free cash flow was $217 million, down 24.6%. It paid out $310 million in dividends and buybacks, 143% of free cash flow. The diluted share count fell 5.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Revenue and margins
Net income and earnings per share
From fiscal 2017 to 2025, earnings per share grew 59.7% a year and net income 64.4% a year, as new shares raised the share count by 15% and diluted each share's earnings.
Returns on capital
Cash flow
Payouts and share count
Valuation
Two ways to value Option Care Health yourself, both starting from its filings: a discounted cash flow model and the price-to-earnings method.
Discounted cash flow (DCF)
A discounted cash flow (DCF) model values a business as the cash it may generate in future, discounted back to today. The starting figures come from Option Care Health's 10-K (or, for net cash and shares, its latest 10-Q) and the assumptions are yours: start from one of three example scenarios, then change any figure to see what it implies for a share, and how that compares with the last share price.
Value per share on three example scenarios, from Option Care Health's fiscal 2025 free cash flow of $217M, net cash of −$928M at December 31, 2025 and 163 million diluted shares, from its filings. The scenarios are fitted to Option Care Health: the base scenario's growth in years 1 to 5 is its revenue growth over the last 3 years, 12.7% a year; the cautious and optimistic ones are lower and higher, and growth in years 6 to 10 is halfway to the long-run rate. The base scenario's discount rate is 10%: 9% for a business of moderate risk (Health Care Facilities), plus 1 point as a smaller company, worth $4.9B; the cautious and optimistic ones use a point more and a point less. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $31.23
- Value on these assumptions, against the last close
- —
- Cash flows in years 1 to 10, valued today
- —
- Everything after year 10, valued today
- —
- Plus net cash
- —
- Share of value from after year 10
How the value changes with two assumptions
Price-to-earnings (P/E) method
Another common way to value a company is to multiply its earnings per share by a price-to-earnings (P/E) multiple: the number of years of today's earnings an investor pays for a share. A higher multiple usually means investors expect earnings to grow. Choose a multiple, for example from similar companies, to see the value it gives.
Value per share on three example scenarios, from Option Care Health's earnings per share of $1.28 (over the last four quarters). Each grows earnings for a year at the cash flow scenarios' rates and applies a multiple to next year's earnings: 27.7×, the middle of Option Care Health's own P/E today, its peers' median and its sector's median (its peers' median) for the base scenario, 20% less and more for the cautious and optimistic ones. The price is brought back a year at 11%, 10% and 9%. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $31.23
- Value at this multiple, against the last close
- —
- Option Care Health's P/E at the last close
- 24.4×
| Company | Last close | Earnings per share | P/E today |
|---|---|---|---|
| Astrana HealthASTH | $37.23 | $0.83 | 44.9× |
| Ensign GroupENSG | $176.92 | $6.38 | 27.7× |
| Option Care HealthOPCH | $31.23 | $1.28 | 24.4× |
| Encompass HealthEHC | $124.10 | $6.14 | 20.2× |
Balance sheet
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 119 | 294 | 344 | 413 | 233 |
| Debt incl. finance leases | 1,066 | 1,064 | 1,063 | 1,111 | 1,161 |
| Net debt (negative means net cash) | 947 | 770 | 719 | 699 | 928 |
| Net debt to EBITDA | 3.7x | 2.6x | 1.9x | 1.8x | 2.3x |
| Debt to equity | 0.9x | 0.8x | 0.8x | 0.8x | 0.9x |
| Interest coverage | 2.9x | 4.5x | 6.1x | 6.6x | 6.2x |
| Current ratio | 1.6x | 1.8x | 1.8x | 1.7x | 1.5x |
| Quick ratio | 1.1x | 1.4x | 1.3x | 1.2x | 1.0x |
Insider trades
Over the 12 months between October 27, 2025 and October 26, 2026, 4 insiders bought $2.9 million of Option Care Health shares on the open market, and 2 insiders sold $1.2 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 7, 2026 | Timothy P SullivanDirector | Bought | 24,154 | $20.69 | $499,746 | Form 4 |
| May 4, 2026 | Harry M Jansen Kraemer JrDirector | Bought | 36,610 | $21.41 | $783,820 | Form 4 |
| May 4, 2026 | Meenal SethnaChief Financial Officer | Bought | 16,225 | $20.16 | $327,096 | Form 4 |
| May 4, 2026 | John Charles RademacherChief Executive Officer, Director | Bought | 12,500 | $21.18 | $264,750 | Form 4 |
| Feb 27, 2026 | Pate R CarterDirector | Sold | 30,287 | $32.05 | $970,698 | Form 4 |
| Feb 27, 2026 | Michael BavaroChief Human Resources Officer | Sold | 6,000 | $33.00 | $198,000 | Form 4 |
| Nov 3, 2025 | Harry M Jansen Kraemer JrDirector | Bought | 38,000 | $25.98 | $987,240 | Form 4 |
Piotroski F-score
The F-score counts how many of nine simple tests of profitability, funding and efficiency a company passed in a year (Piotroski, 2000). The more tests passed, the stronger the year: 8 or 9 is strong, 0 to 2 weak. Companies that report no gross profit are scored on the other eight.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Fail |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Pass | Pass | Pass |
| Gross margin rose | Pass | Fail | Fail |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 8 of 9 | 6 of 9 | 5 of 9 |
| Accruals ratio | −3.3% | −3.4% | −1.5% |
Compare
Put Option Care Health side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Option Care Health | FY25 | 13.0% | 6.0% | 3.8% | 11.4% | 2.3x | 5 | |
| Encompass Health | FY25 | 10.5% | — | 7.4% | 15.8% | 1.7x | 8 | Compare |
| Ensign Group | FY25 | 18.7% | 8.4% | — | 19.7% | −0.8x | 6 | Compare |
| Acadia Healthcare | FY25 | 5.0% | — | −13.3% | −16.0% | — | 4 | Compare |
| Astrana Health | FY25 | 56.4% | 2.5% | 3.3% | 4.2% | 4.9x | 4 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 936 | 1,828 | 1,940 | 2,310 | 3,033 | 3,439 | 3,945 | 4,302 | 4,998 | 5,650 |
| Revenue growth | — | 95.4% | 6.1% | 19.1% | 31.3% | 13.4% | 14.7% | 9.1% | 16.2% | 13.0% |
| Gross profit | 262 | 446 | 422 | 513 | 682 | 780 | 867 | 981 | 1,013 | 1,088 |
| Research and development | — | — | — | — | — | — | — | — | — | — |
| Operating income | −11 | 27 | 38 | −0 | 111 | 191 | 240 | 315 | 322 | 338 |
| Net income | −43 | 4 | −6 | −76 | −8 | 140 | 151 | 267 | 212 | 208 |
| Diluted EPS (US$) | −0.55 | 0.03 | −0.04 | −0.49 | −0.04 | 0.77 | 0.83 | 1.48 | 1.23 | 1.27 |
| Diluted shares (millions) | 94 | 143 | 143 | 156 | 181 | 181 | 182 | 180 | 173 | 163 |
| Cash flow | ||||||||||
| Cash from operations | −42 | 38 | 24 | 40 | 127 | 209 | 268 | 371 | 323 | 258 |
| Capital expenditure | — | 25 | 26 | 28 | 27 | 26 | 35 | 42 | 36 | 41 |
| Free cash flow | — | 13 | −2 | 11 | 101 | 183 | 232 | 329 | 288 | 217 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 250 | 253 | 310 |
| Acquisitions | 68 | 0 | 11 | 700 | 0 | 86 | 87 | 12 | 0 | 117 |
| Stock-based compensation | 2 | 2 | 2 | 4 | 3 | 10 | 17 | 30 | 36 | 40 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 10 | 40 | 36 | 67 | 99 | 119 | 294 | 344 | 413 | 233 |
| Debt incl. finance leases | 468 | 503 | 539 | 1,287 | 1,124 | 1,066 | 1,064 | 1,063 | 1,111 | 1,161 |
| Total assets | 605 | 603 | 1,428 | 2,590 | 2,647 | 2,791 | 3,113 | 3,217 | 3,422 | 3,456 |
| Total liabilities | 567 | 606 | 825 | 1,683 | 1,632 | 1,615 | 1,727 | 1,795 | 2,018 | 2,129 |
| Shareholders' equity | 601 | 606 | 603 | 907 | 1,016 | 1,176 | 1,386 | 1,422 | 1,404 | 1,326 |
| Margins and ratios | ||||||||||
| Gross margin | 28.0% | 24.4% | 21.8% | 22.2% | 22.5% | 22.7% | 22.0% | 22.8% | 20.3% | 19.3% |
| Operating margin | −1.2% | 1.5% | 2.0% | −0.0% | 3.6% | 5.5% | 6.1% | 7.3% | 6.4% | 6.0% |
| Net margin | −4.6% | 0.2% | −0.3% | −3.3% | −0.3% | 4.1% | 3.8% | 6.2% | 4.2% | 3.7% |
| Free cash flow margin | — | 0.7% | −0.1% | 0.5% | 3.3% | 5.3% | 5.9% | 7.7% | 5.8% | 3.8% |
| Return on capital | −1.2% | 2.0% | 2.8% | −0.0% | 4.2% | 9.2% | 8.2% | 10.9% | 11.3% | 11.4% |
| Return on equity | −16.5% | 0.6% | −1.0% | −10.1% | −0.8% | 12.8% | 11.8% | 19.0% | 15.0% | 15.2% |
| Return on assets | −7.5% | 0.6% | −0.6% | −3.8% | −0.3% | 5.1% | 5.1% | 8.4% | 6.4% | 6.0% |
| Net debt to EBITDA | 41.5x | 7.5x | 6.6x | 22.9x | 5.6x | 3.7x | 2.6x | 1.9x | 1.8x | 2.3x |